We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+13.99%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$216M
AUM Growth
+$6.9M
Cap. Flow
-$12.7M
Cap. Flow %
-5.89%
Top 10 Hldgs %
39.36%
Holding
92
New
7
Increased
29
Reduced
20
Closed
8

Top Buys

Rank Stock Value
1
EVO icon
Evotec
EVO
+$1.42M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$1.3M
3
AMGN icon
Amgen
AMGN
+$1.04M
4
GDX icon
VanEck Gold Miners ETF
GDX
+$620K
5
GPCR icon
Structure Therapeutics
GPCR
+$544K

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$908K
2
XLE icon
State Street Energy Select Sector SPDR ETF
XLE
+$562K
3
XNCR icon
Xencor
XNCR
+$558K
4
ORCL icon
Oracle
ORCL
+$484K
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$462K

Sector Composition

Rank Sector Weight
1 Healthcare 30.72%
2 Technology 27.13%
3 Consumer Discretionary 7.96%
4 Communication Services 7.9%
5 Financials 4.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
C icon
26
Citigroup
C
$214B
$3.06M 1.42%
36,000
-1,500
-4% -$108K
TEVA icon
27
Teva Pharmaceuticals
TEVA
$40.1B
$3.06M 1.42%
182,500
+11,500
+7% +$186K
CRVS icon
28
Corvus Pharmaceuticals
CRVS
$1.1B
$3.03M 1.4%
757,500
+357,500
+89% +$1.3M
AMGN icon
29
Amgen
AMGN
$209B
$2.93M 1.36%
10,500
+3,675
+54% +$1.04M
INCY icon
30
Incyte
INCY
$25.5B
$2.83M 1.31%
41,500
-3,500
-8% -$222K
ZBH icon
31
Zimmer Biomet
ZBH
$18.8B
$2.8M 1.3%
30,650
+3,846
+14% +$372K
ZM icon
32
Zoom
ZM
$27.1B
$2.65M 1.23%
34,000
+6,500
+24% +$503K
BNED icon
33
Barnes & Noble Education
BNED
$433M
$2.54M 1.18%
215,943
+10,500
+5% +$112K
MRVL icon
34
Marvell Technology
MRVL
$149B
$2.44M 1.13%
31,500
+4,000
+15% +$250K
AOD
35
abrdn Total Dynamic Dividend Fund
AOD
$1.08B
$2.36M 1.09%
266,000
– –
URNM icon
36
Sprott Uranium Miners ETF
URNM
$1.71B
$2.03M 0.94%
42,400
– –
JQC icon
37
Nuveen Credit Strategies Income Fund
JQC
$704M
$2M 0.93%
371,713
+47,000
+14% +$246K
ABBV icon
38
AbbVie
ABBV
$466B
$2M 0.92%
10,750
– –
AAPL icon
39
Apple
AAPL
$4.98T
$1.8M 0.83%
8,750
+750
+9% +$151K
AVGO icon
40
Broadcom
AVGO
$1.78T
$1.76M 0.81%
6,375
+1,375
+28% +$299K
HELP
41
Cybin Inc
HELP
$487M
$1.7M 0.79%
202,750
+750
+0.4% +$5.46K
LNSR icon
42
LENSAR
LNSR
$64.4M
$1.57M 0.73%
119,217
+3,500
+3% +$47.3K
META icon
43
Meta Platforms (Facebook)
META
$1.48T
$1.48M 0.68%
2,000
– –
GDXJ icon
44
VanEck Junior Gold Miners ETF
GDXJ
$6.91B
$1.45M 0.67%
21,500
– –
B
45
Barrick Mining
B
$61B
$1.25M 0.58%
60,000
-5,000
-8% -$97.7K
PFE icon
46
Pfizer
PFE
$143B
$1.24M 0.58%
51,350
– –
QCOM icon
47
Qualcomm
QCOM
$165B
$1.23M 0.57%
7,750
– –
GM icon
48
General Motors
GM
$80.8B
$1.23M 0.57%
25,000
– –
BOXX icon
49
Alpha Architect 1-3 Month Box ETF
BOXX
$13.1B
$1.13M 0.52%
10,000
– –
XNCR icon
50
Xencor
XNCR
$1.43B
$1.1M 0.51%
140,000
-62,167
-31% -$558K
1
2
3 4

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
AWM
Able Wealth Management Toms River, New Jersey $374M AUM 12.51% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return

DCF Advisers's Q2 2025 Portfolio in Review

As of Q2 2025, DCF Advisers held 92 positions worth $216M, up 3.3% from $209M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

DCF Advisers withdrew a net $12.7M in Q2 2025, closing 8 positions and reducing 20 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $462K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, DCF Advisers opened a new position in Structure Therapeutics worth $513K.

  • DCF Advisers's largest Q2 2025 buy was Structure Therapeutics: 24,750 shares worth $513K.
  • DCF Advisers added most to Evotec in Q2 2025, an estimated $1.42M increase.
  • DCF Advisers's biggest Q2 2025 reduction was SPDR Gold Trust, cutting an estimated $908K.
  • DCF Advisers fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $462K.
  • DCF Advisers's ten largest holdings make up 39% of its $216M portfolio in Q2 2025.
  • DCF Advisers opened 7 new positions and closed 8 in Q2 2025.
  • DCF Advisers's portfolio value rose 3.3% quarter-over-quarter to $216M.

Based on DCF Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.